Which medications in the drug class Antiparkinson Agents, COMT Inhibitors are used in the treatment of Multiple System Atrophy?

Updated: Oct 17, 2018
  • Author: André Diedrich, MD, PhD; Chief Editor: Selim R Benbadis, MD  more...
  • Print

Antiparkinson Agents, COMT Inhibitors

Patients with MSA may have an initial response to levodopa, but this response usually diminishes over time. Withdrawal of levodopa can cause a patient's condition to deteriorate, but this is much more prominent in Parkinson disease than in MSA. In modern practice, levodopa is administered in combination with a dopa decarboxylase inhibitor.

Levodopa/Carbidopa (Sinemet, Parcopa)

In this combination, levodopa is administered with a dopa decarboxylase inhibitor. When levodopa is administered alone, it is largely decarboxylated by the intestinal mucosa or other peripheral sites rich in monoamine oxidase (MAO), and little reaches the cerebral circulation and CNS.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!